Lion Point Capital, Lp

Institutional manager — quarterly 13F holdings, Q ending 2026-03-31

Reported value
$16.7M
Q ending 2026-03-31
Prior quarter
$19.3M
Q ending 2025-12-31
Change
-13.4% QoQ · +6.7% YoY
Positions
35
reported holdings

Largest positions

All 35 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
HoldingTickerTypeValueShares
Praxis Precision Medicines IPRAXShares$1.4M4K
Moonlake ImmunotherapeuticsMLTXShares$1.3M68K
Royalty Pharma PlcShares$1.0M21K
Milestone Pharmaceuticals InMISTShares$976K820K
Geron CorpGERNShares$861K578K
Syndax Pharmaceuticals IncSNDXShares$841K36K
Ardelyx IncARDXShares$771K129K
Fennec Pharmaceuticals IncFENCShares$691K112K
Benitec Biopharma IncBNTCShares$660K62K
Sarepta Therapeutics IncSRPTShares$620K29K
Disc Medicine IncIRONShares$518K8K
Cue Biopharma IncCUE1EURShares$506K2.2M
Compass Pathways PlcCMPSShares$442K80K
Biohaven LtdShares$437K52K
Lantheus Hldgs IncLNTHShares$417K6K
Jasper Therapeutics IncJSPRShares$407K465K
Humacyte IncHUMAShares$394K650K
Viatris IncVTRSShares$374K28K
Kura Oncology IncKURAShares$374K46K
Bridgebio Pharma IncBBIOShares$371K5K
Dyne Therapeutics IncDYNShares$326K18K
Rocket Pharmaceuticals IncRCKTShares$308K86K
Pacira Biosciences IncPCRXShares$305K14K
Edgewise Therapeutics IncEWTXShares$287K9K
Mineralys Therapeutics IncMLYSShares$284K11K
Seres Therapeutics IncMCRBShares$280K32K
Janux Therapeutics IncJANXShares$264K19K
Uniqure NvShares$240K15K
Regenxbio IncRGNXShares$223K27K
Azenta IncAZTAShares$205K10K
Innoviva IncINVAShares$191K8K
Gh Research PlcShares$143K10K
Arcutis Biotherapeutics IncARQTShares$124K5K
Innate Pharma S AIPHAShares$104K81K
Spruce Biosciences IncSPRBShares$65K1K

Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.